Tag: Beigene

FDA, Regulations

BeiGene’s Tevimbra receives FDA approval to treat advanced oesophageal cancer

March 18, 2024


The authorisation specifically applies to adult patients with unresectable or metastatic ESCC after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. Oesophageal cancer is the sixth most common cause of cancer-related deaths globally and ESCC accounts for almost […]

FDA, Regulations

BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia

January 23, 2023


The FDA’s decision was based on two global head-to-head phase 3 clinical trials in which Brukinsa – a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) – demonstrated superior efficacy against Janssen’s Imbruvica (ibrutinib) in patients with relapsed/refractory CLL or […]

Cell and Gene Therapy, Industry

Beigene expands into cancer cell therapy with Shoreline pact

June 9, 2021

Via: Biopharma Dive

Beigene has quickly become a force in cancer drug development, earning approvals in the U.S. and China for its targeted therapy Brukinsa and immunotherapy tislelizumab. The biotech is developing a slate of small molecule and antibody drugs aimed at several […]